Pioneering work by Gabriel G. Haddad circumvented this barrier by reprogramming peripheral blood mononuclear cells (PBMCs) from chronic mountain sickness (CMS) patients and controls into induced pluripotent stem cell (iPSC)-derived CD34+ hematopoietic progenitors (Azad et al., 2016). This evidence concerns the gene CD34 and congenital myasthenic syndrome.